Company: KROS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001664710-25-000070
Chunk: 300

Company: Keros Therapeutics, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Item 8
Chunk 300
---
525 664 (139)$43,503 $40,515 $2,988 

Research and development expenses were $43.5 million for the three months ended June 30, 2025, compared to $40.5 million for the three months ended June 30, 2024. The increase of $3.0 million was primarily due to (i) an increase of $4.6 million of elritercept-related expenses, primarily driven by an increase of $4.3 million in clinical spend associated with our ongoing Phase 2 clinical trials, one in patients with MDS and one in patients with myelofibrosis, and the advancement of a 

26

Phase 3 clinical trial in patients with MDS, and an increase of $0.3 million in manufacturing activities; (ii) an increase of $1.9 million related to personnel expenses, including an increase of $0.3 million of additional stock-based compensation costs, driven by increased severance costs; and (iii) a net increase of $1.4 million in facilities, supplies, professional fees and other expenses. These increases were partially offset by (a) a decrease of $1.5 million of KER-065-related expenses, primarily driven by a decrease of $0.9 million in clinical spend associated with our Phase 1 clinical trial and a net decrease of $0.6 million in manufacturing and preclinical activities; (b) a decrease of $2.7 million of cibotercept-related expenses, primarily driven by a decrease of $2.1 million in clinical spend associated with our Phase 2 clinical trial and a net decrease of $0.6 million in manufacturing and preclinical activities; and (c) a decrease of $0.8 million in preclinical pipeline and development activities. We expect research and development expenses to fluctuate from quarter to quarter depending on the timing of clinical trial activities, clinical manufacturing and other development activities. We expect that elritercept-related expenses will decrease once transitioned to Takeda.

General and Administrative Expenses 

General and administrative expenses were $14.5 million for the three months ended June 30, 2025, compared to $10.0 million for the three months ended June 30, 2024. The increase of approximately $4.5 million was primarily due to (i) a net increase of $4.5 million in professional fees, insurance, facilities, supplies and other expenses and (ii) a net increase